title: [Comparison of ACR/EULAR remission criterion of rheumatoid arthritis published in 2011 year with the other common remission criteria].
abstract: OBJECTIVE
  To evaluate and compare the advantage and utility of the 2011 ACR/EULAR criterion and the other remission criteria of rheumatoid arthritis.
  
  
  METHODS
  The questionnaires for RA patients were used for the study. The remission rate and residual disease activity of RA patients were compared according to four criteria of remission, including 2011 ACR/EULAR remission criterion, DAS28, CDAI and ACR.
  
  
  RESULTS
  Among the 310 cases, 254 effective questionnaires were obtained. The remission rates of ACR, CDAI,ACR/EULAR and DAS28 were 15.4%, 23.2%,25.2%,38.2%, respectively.ACR criteria is the most stringent criteria, the remission rate of ACR was significantly lower than the other three criteria (P<0.05). There was no residual disease activity of ACR criteria. DAS28 criteria is the laxest criteria,the remission rate and residual disease activity of DAS28 was significantly higher than the other three criteria (P<0.05).There was no difference between CDAI and ACR/EULAR, which were more suitable for clinical practice.
  
  
  CONCLUSIONS
  Among the four criteria, ACR criteria is the most stringent criteria, DAS28 criteria is the laxest criteria, The CDAI and ACR/EULAR criteria were more suitable for clinical practice.
authors.affiliation: Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Lu
authors.forename: Chun
authors.initials: C
authors.lastname: Li
authors.forename: Jin-xia
authors.initials: JX
authors.lastname: Zhao
authors.forename: Zhan-guo
authors.initials: ZG
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods*; D012074:Remission Induction; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents